Clinical Trials Update

CLINICAL TRIAL UPDATE

DRY AMD
► Study: Sirolimus to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration Sponsor: National Eye Institute Purpose: To examine the safety and effectiveness of sirolimus in preserving vision in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) Design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study Number of Patients: 15 Inclusion Criteria: Participant must have at least 1/2 disc area (approximately 1 mm²) of GA compatible with AMD present in each eye. GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the RPE, typically with exposure of underlying choroidal blood vessels. Even if much of the RPE appears to be preserved and large choroidal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA. The GA in each eye must be able to be photographed in its entirety; participant must have at least one large drusen (greater than 125 micro meter) in each eye; participant must have a steady fixation in both eyes in the foveal or parafoveal area and media clear enough for good quality photographs. This will permit randomization; participant must have VA between 20/20 and 20/400 in each eye Exclusion Critieria: Participant has evidence of ocular disease other than AMD in either eye that may confound the outcome of the study (eg, diabetic retinopathy with 10 or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, moderate/severe myopia, etc.); Participant has any of the following a) a history of macular laser, b) a history of photodynamic therapy (PDT), c) received an intravitreal injection of any agent (not an anti-VEGF agent) within 4 months prior to study enrollment) or received topical treatment of any agent for advanced AMD within 1 month prior to enrollment. Participants currently taking or who have previously taken AREDS vitamin supplementation are not excluded; participant has had a vitrectomy; participant is expected to need ocular surgery during the course of the trial; participant has undergone lens removal in the last 3 months or YAG laser capsulotomy within the last month; participant is on chemotherapy; participant is on immunosuppressive medication; participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve; participant with a history of malignancy that would compromise the 2-year study survival; participant with a history of ocular herpes simplex virus (HSV) Information: (800) 411-1222 ► Study: A Multi-Center Study of Reading Rehabilitation in Macular Disease Sponsor: Department of Veteran Affairs Purpose: To measure the effectiveness of a newly-designed oculomotor training program for patients with macular disease, including AMD Design: Randomized, Double Blind (Subject, Outcomes Assessor), Crossover Assignment, Efficacy Study Number of Patients: 120 Inclusion Criteria: Patients with a diagnosis of macular disease, such as AMD; an established preferred retinal locus; VA of less than or equal to 20/70 and greater than or equal to 20/400 (in the better eye) Exclusion Criteria: Those with other major ophthalmologic and neurologic disease, choroidal neovascularization ("wet" AMD), moderate to severe media opacities, and cognitive impairment Information: pdgrant@uic.edu ► Study: GATE: Geographic Atrophy Treatment Evaluation Sponsor: Alcon Research Purpose: To evaluate AL-8309B as a topical ocular treatment for geographic atrophy secondary to AMD Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment Number of Patients: 550 Inclusion Criteria: Patient must state the ability to administer eye drops or have a caretaker to administer the eye drops; well-demarcated area of atrophy secondary to AMD if the lesion is multifocal, at least 1 focal lesion must be equal to or larger than 1.25 mm² [0.5 disc areas (DA)]; total lesion size must be less than or equal to 20 mm² (8 DA); presence of hyperautofluorescence adjacent to an area of atrophy; no evidence of CNV; BCVA of 35 letters (20/200 Snellen equivalent) or better; clear ocular media and adequate pupillary dilation to permit good quality photographic imaging Exclusion Criteria: Ocular disease in the study eye that in the opinion of the Investigator may confound assessment of the retina or affect central vision, other than non-exudative AMD [eg, branch retinal vein occlusion (BRVO), diabetic retinopathy, uveitis]; history of cataract surgery in either eye within the past 3 months of screening (Visit 1); history or evidence of serious ocular trauma or intraocular surgery (eg, LASIK, keratoplasty) in either eye within the past 6 months of screening (Visit 1); evidence of significant uncontrolled comorbidity or condition with a limited survival prognosis (eg, cancer, severe/unstable cardiovascular disease) that would make participation in the trial or adherence to the study schedule difficult or unlikely Information: medical.information@alconlabs.com ► Study: Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration Sponsor: Pfizer Purpose: To determine the safety and tolerability of RN6G in patients with dry AMD Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Single Group Assignment, Safety Study Number of Patients: 45 Inclusion Criteria: Diagnosis of dry AMD as defined by the Age-Related Eye Disease Study (AREDS, 2005), including uni- or multi-focal GA, without foveal involvement; BCVA of 20/320 or better in the worst eye Exclusion Criteria: Diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions; diagnosis or history of Alzheimer's disease, dementia or neurodegenerative disorders; diagnosis or recent history of clinically significant cerebrovascular disease; uncontrolled hypertension; uncontrolled Type 1 or Type 2 diabetes mellitus Information: (800) 718-1021 ► Study: Fluocinolone Acentonide Intravitreal Inserts in Geographic Atrophy Sponsor: Alimera Sciences Purpose: To compare the safety and efficacy of Medidur FA treatment in 1 eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study Number of Patients: 40 Inclusion Criteria: Clinical diagnosis bilateral GA secondary to AMD of >0.5 and <7 MPS DAs; males and non-pregnant females 55 years old or older Exclusion Critieria: GA secondary to any condition other than AMD in either eye; history of or current CNV in either eye or the need for antiangiogenic therapy; glaucoma or ocular hypertension (IOP >21 mm Hg OR concurrent therapy at screening with IOP-lowering agents) in either eye; treatment with intravitreal, subtenon, or periocular steroid within 6 months prior to enrollment in either eye; any change in systemic steroid therapy within 3 months of screening Information: lschulz@med.wayne.edu ► Study: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-Related Macular Degeneration Sponsor: The New York Eye and Ear Infirmary Information: ktai@nyee.edu ► Study: Safety Study in Retinal Transplantation for Dry Age-Related Macular Degeneration Sponsor: Ocular Transplantation; National Neurovision Research Institute Information: nradtke@prodigy.net ► Study: Safety and Tolerability of ACU-02 in Healthy Volunteers for Potential Therapy for Dry Age-related Macular Degeneration Sponsor: Acucela Inc. Information: www.acucela.com ► Study: Pilot Study of the Evaluation of Subconjunctival Sirolimus the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration Sponsor: National Eye Institute Information: lschulz@med.wayne.edu

DRY AMD

► Study: Sirolimus to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration
Sponsor: National Eye Institute
Purpose: To examine the safety and effectiveness of sirolimus in preserving vision in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Number of Patients: 15
Inclusion Criteria: Participant must have at least 1/2 disc area (approximately 1 mm²) of GA compatible with AMD present in each eye. GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the RPE, typically with exposure of underlying choroidal blood vessels. Even if much of the RPE appears to be preserved and large choroidal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA. The GA in each eye must be able to be photographed in its entirety; participant must have at least one large drusen (greater than 125 micro meter) in each eye; participant must have a steady fixation in both eyes in the foveal or parafoveal area and media clear enough for good quality photographs. This will permit randomization; participant must have VA between 20/20 and 20/400 in each eye
Exclusion Critieria: Participant has evidence of ocular disease other than AMD in either eye that may confound the outcome of the study (eg, diabetic retinopathy with 10 or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, moderate/severe myopia, etc.); Participant has any of the following a) a history of macular laser, b) a history of photodynamic therapy (PDT), c) received an intravitreal injection of any agent (not an anti-VEGF agent) within 4 months prior to study enrollment) or received topical treatment of any agent for advanced AMD within 1 month prior to enrollment. Participants currently taking or who have previously taken AREDS vitamin supplementation are not excluded; participant has had a vitrectomy; participant is expected to need ocular surgery during the course of the trial; participant has undergone lens removal in the last 3 months or YAG laser capsulotomy within the last month; participant is on chemotherapy; participant is on immunosuppressive medication; participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve; participant with a history of malignancy that would compromise the 2-year study survival; participant with a history of ocular herpes simplex virus (HSV)
Information: (800) 411-1222

► Study: A Multi-Center Study of Reading Rehabilitation in Macular Disease
Sponsor: Department of Veteran Affairs
Purpose: To measure the effectiveness of a newly-designed oculomotor training program for patients with macular disease, including AMD
Design: Randomized, Double Blind (Subject, Outcomes Assessor), Crossover Assignment, Efficacy Study
Number of Patients: 120
Inclusion Criteria: Patients with a diagnosis of macular disease, such as AMD; an established preferred retinal locus; VA of less than or equal to 20/70 and greater than or equal to 20/400 (in the better eye)
Exclusion Criteria: Those with other major ophthalmologic and neurologic disease, choroidal neovascularization ("wet" AMD), moderate to severe media opacities, and cognitive impairment
Information: pdgrant@uic.edu

► Study: GATE: Geographic Atrophy Treatment Evaluation
Sponsor: Alcon Research
Purpose: To evaluate AL-8309B as a topical ocular treatment for geographic atrophy secondary to AMD
Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment
Number of Patients: 550
Inclusion Criteria: Patient must state the ability to administer eye drops or have a caretaker to administer the eye drops; well-demarcated area of atrophy secondary to AMD if the lesion is multifocal, at least 1 focal lesion must be equal to or larger than 1.25 mm² [0.5 disc areas (DA)]; total lesion size must be less than or equal to 20 mm² (8 DA); presence of hyperautofluorescence adjacent to an area of atrophy; no evidence of CNV; BCVA of 35 letters (20/200 Snellen equivalent) or better; clear ocular media and adequate pupillary dilation to permit good quality photographic imaging
Exclusion Criteria: Ocular disease in the study eye that in the opinion of the Investigator may confound assessment of the retina or affect central vision, other than non-exudative AMD [eg, branch retinal vein occlusion (BRVO), diabetic retinopathy, uveitis]; history of cataract surgery in either eye within the past 3 months of screening (Visit 1); history or evidence of serious ocular trauma or intraocular surgery (eg, LASIK, keratoplasty) in either eye within the past 6 months of screening (Visit 1); evidence of significant uncontrolled comorbidity or condition with a limited survival prognosis (eg, cancer, severe/unstable cardiovascular disease) that would make participation in the trial or adherence to the study schedule difficult or unlikely
Information: medical.information@alconlabs.com

► Study: Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Sponsor: Pfizer
Purpose: To determine the safety and tolerability of RN6G in patients with dry AMD
Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Single Group Assignment, Safety Study
Number of Patients: 45
Inclusion Criteria: Diagnosis of dry AMD as defined by the Age-Related Eye Disease Study (AREDS, 2005), including uni- or multi-focal GA, without foveal involvement; BCVA of 20/320 or better in the worst eye
Exclusion Criteria: Diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions; diagnosis or history of Alzheimer's disease, dementia or neurodegenerative disorders; diagnosis or recent history of clinically significant cerebrovascular disease; uncontrolled hypertension; uncontrolled Type 1 or Type 2 diabetes mellitus
Information: (800) 718-1021

► Study: Fluocinolone Acentonide Intravitreal Inserts in Geographic Atrophy
Sponsor: Alimera Sciences
Purpose: To compare the safety and efficacy of Medidur FA treatment in 1 eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD
Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Number of Patients: 40
Inclusion Criteria: Clinical diagnosis bilateral GA secondary to AMD of >0.5 and <7 MPS DAs; males and non-pregnant females 55 years old or older
Exclusion Critieria: GA secondary to any condition other than AMD in either eye; history of or current CNV in either eye or the need for antiangiogenic therapy; glaucoma or ocular hypertension (IOP >21 mm Hg OR concurrent therapy at screening with IOP-lowering agents) in either eye; treatment with intravitreal, subtenon, or periocular steroid within 6 months prior to enrollment in either eye; any change in systemic steroid therapy within 3 months of screening
Information: lschulz@med.wayne.edu

► Study: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-Related Macular Degeneration
Sponsor: The New York Eye and Ear Infirmary
Information: ktai@nyee.edu

► Study: Safety Study in Retinal Transplantation for Dry Age-Related Macular Degeneration
Sponsor: Ocular Transplantation; National Neurovision Research Institute
Information: nradtke@prodigy.net

► Study: Safety and Tolerability of ACU-02 in Healthy Volunteers for Potential Therapy for Dry Age-related Macular Degeneration
Sponsor: Acucela Inc.
Information: www.acucela.com

► Study: Pilot Study of the Evaluation of Subconjunctival Sirolimus the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Sponsor: National Eye Institute
Information: lschulz@med.wayne.edu

WET AMD
► Study: A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Sponsor: Genentech Purpose: To study the efficacy and safety of ranibizumab injection administered intravitreally to patients with CNV secondary to AMD Design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment Number of Patients: 1100 Inclusion Criteria: For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study; CNV lesions with classic CNV component, occult CNV, or with some classic CNV component are permissible Exclusion Criteria: History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye; prior treatment with Visudyne, external-beam radiation therapy, or TTT in the study eye; previous intravitreal drug delivery (eg, intravitreal corticosteroid injection, anti-angiogenic drugs, or device implantation) in the study eye; previous treatment or participation in a clinical trial involving antiangiogenic drugs (Avastin, anecortave acetate, protein kinase C inhibitors, etc.), in the non-study eye within 3 months of Day 0. The patient may not have received Lucentis or Macugen in the nonstudy eye within 7 days of Day 0; treatment with Visudyne in the non-study eye < 7 days preceding Day 0; subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either > 50% of the total area of the lesion or > 1 disc area (2.54 mm²) in size; subfoveal fibrosis or atrophy in the study eye; CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia; retinal pigment epithelial tear involving the macula in the study eye; any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could either: require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 24-month study period Information: lane.hayley@gene.com ► Study: A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration Sponsor: Ophthotech Corporation Purpose: To evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) Design: Treatment, Nonrandomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study Number of Patients: 50 Inclusion Criteria: Subfoveal choroidal neovascularization (CNV) due to AMD (ie, predominantly classic, minimally classic or occult no classic) as documented by fluorescein angiogram Exclusion Criteria: Any prior treatment for AMD or any intravitreal treatment for any indication in the study eye prior to the screening visit, except oral supplements of vitamins and minerals; previous or concomitant therapy with intravitreous corticosteroids; diabetic retinopathy; history or evidence of severe cardiac disease (eg, NYHA Functional Class III or IV - see Appendix 19.6); history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment; history or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation; clinically significant impaired renal (serum creatinine >2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. Patients with results outside these ranges may be enrolled in consultation with Ophthotech Information: (212) 845-8214 ► Study: Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab Sponsor: National Eye Institute Purpose: To measure antibody levels in the blood of people with bleeding or swelling in the retina who have or have not been treated with bevacizumab or ranibizumab Design: Prospective Number of Patients: 30 Inclusion Criteria: Subjects will include adults being treated for exudative AMD, or macular edema secondary to DR or venous occlusion Exclusion Criteria: Patients who are currently receiving any form of systemic immunosuppressive or immunomodulatory therapy, including corticosteroids; patients who have autoimmune or rheumatologic disease; patients with evidence of active systemic infection Information: prpl@mail.cc.nih.gov ► Study: EMERALD: Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis in Patients With Age-Related Macular Degeneration Sponsor: MacuSight, Inc. Purpose: To determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study Number of Patients: 60 Inclusion Criteria: Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration within 6 months of initial study visit, and may have been treated with up to 3 Lucentis (ranibizumab) or 3 Avastin (bevacizumab) injections with the last injection administered at least 4 weeks prior to the initial study visit, or is treatment-naïve; VA of 20/40 to 20/200 in the study eye Exclusion Criteria: Any other ocular disease that could compromise vision in the study eye; presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration Information: cdelpouys@macusight.com ► Study: ROSE: A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy Sponsor: NeoVista Purpose: To evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age-related macular degeneration that have failed primary anti-VEGF therapy Design: Treatment, Nonrandomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Number of Patients: 20 Inclusion Criteria: Subjects must have predominantly classic, minimally classic, or occult with no classic lesions, as determined by the Investigator, secondary to AMD, with a total lesion size (including blood, scarring, and neovascularization) of <12 total disc areas (21.24mm²), and a GLD ≥5.4 mm; subjects must have received a minimum of 3 prior injections (a minimum of 3 prior injections of the same compound) of anti-VEGF therapy (Lucentis or Avastin, subjects may have been treated previously with Macugen, but must have been most recently treated with Lucentis or Avastin and met the criteria for failure below) with evidence of "failure" to respond to therapy; subjects must be age 50 or older Exclusion Criteria: Subjects with prior or subfoveal CNV therapy with photodynamic therapy, intravitreal or subretinal steroids, or transpupillary thermotherapy (TTT) (Note: This includes subjects with no known history, but with photographic evidence of prior therapy); subjects who underwent previous radiation therapy to the eye, head or neck; subjects who have been previously diagnosed with type 1 or type 2 diabetes mellitus. Subjects who do not have a documented diagnosis but have retinal findings consistent with type 1 or type 2 diabetes mellitus; women of child-bearing potential (female subjects must be postmenopausal or surgically sterilized) Information: clinicaltrials@neovistainc.com ► Study: Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-Related Macular Degeneration Sponsor: Lpath, Inc. Purpose: To assess the safety of iSONEP, which is a humanized monoclonal antibody against a bioactive lipid, sphingosine 1-phosphate (S1P) Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study Number of Patients: 33 Inclusion Criteria: 50 years and older; BCVA ETDRS letter score in study eye between 20-57 letters using ETDRS refraction (Snellen of 20/70-20/400); any CNV secondary to AMD in study eye, classic, minimally classic or occult with leakage on fluorescein angiography and intraretinal or subretinal fluid on OCT; visual acuity in fellow eye must be 20/800 or better at 4 meters Exclusion Criteria: Ocular disease other than CNV that could compromise vision in study eye; systemic immunosuppressive medication/therapy (eg, chemotherapy, steroids); uncontrolled hypertension and/or arrhythmias; QT/QTc interval measurement >450 milliseconds; cancer within the last 2 years except superficial basal or squamous cell skin cancer or cervical carcinoma in situ; have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (>8 D) or CNV secondary to other causes than AMD; any additional ocular diseases which have irreversibly compromised VA of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant DME and severe nonproliferative diabetic retinopathy; any intraocular or general surgery, including cataract surgery, within 2 months of Day 1; history of uveitis in either eye; any ocular or periocular infection within 4 weeks prior to Day 1; active ocular inflammation grade trace and above; cup to disc ratio >0.8, IOP >21 mm Hg in glaucoma subjects treated with more than 2 ocular hypotensive agents; previous pars plana vitrectomy or trabeculectomy in study eye; history of anterior vitrectomy; inability to obtain photographs, FA or OCT to document CNV, eg, due to media opacity, allergy to fluorescein dye, or lack of venous access; aphakia Information: (270) 554-8929 ► Study: Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration Sponsor: Retina Macula Institute Purpose: To assess 2 groups (monthly and PRN therapy) and assess high resolution OCT, microperimetry, and multifocal ERG outcomes Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment Number of Patients: 45 Inclusion Criteria: Age ≥50 years old; patients with active neovascular AMD Exclusion Criteria: Participation in another simultaneous medical investigation or trial; concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); previous PDT therapy; previous intravitreal steroid therapy within last 3 months; previous anti-VEGF therapy in the past month Information: lillian.rmi@gmail.com ► Study: Combination Ranibizumab and Bromfenac for Neovascular Age-Related Macular Degeneration Sponsor: Oregon Health and Science University/Genentech Purpose: To determine whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone Design: Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study Number of Patients: 30 Inclusion Criteria: Age >50 years; patients with active neovascular AMD; if the patient has bilateral disease and qualifies for the study, both eyes may be included Exclusion Criteria: Concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); previous intravitreal steroid or anti-VEGF therapy within last 3 months; patients with a concurrent corneal epithelial disruption or erosion; patients with immune deficiencies that would affect the ability of the cornea to heal; patients with a known sensitivity to any component of the formulations under investigation Information: schainm@ohsu.edu ► Study: ERG/EOG Study in AMD Patients Treated With Ranibizumab Sponsor: Retina Center, Minnesota/Genentech Purpose: To focus on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD Design: Case-Only, Prospective Number of Patients: 10 Inclusion Criteria: Patients to be included in the study must have AMD with choroidal neovascularization; BCVA between 20/20 and 20/400; lesion size ≤12 MPS disc areas Exclusion Criteria: Media insufficient to obtain a view; other causes of CNV not related to AMD; active ocular or periocular infection; ocular surgery within 1 month prior to the study; any other condition the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated; participation in another simultaneous medical investigation or trial; media insufficient to obtain a view; other causes of CNV not related to AMD Information: vu@retinadocs.com ► Study: Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Sponsor: OSI/Pfizer Information: (866) 622-8436 ► Study: LUV: Lucentis Utilizing Visudyne Combination Therapy in the Treatment of Age-Related Macular Degeneration Sponsor: Novartis/Greater Houston Retinal Research Information: http://www.houstonretina.com/ ► Study: A Phase I Trial of a Single Intravitreal Injection of REDD14NP to Patients With CNV Secondary to Wet AMD Sponsor: Quark Biotech, Inc. Information: (212) 452-6902 ► Study: Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced-Fluence PDT in Patients With Wet AMD Sponsor: Barnes Retina Institute Information: bristudies@barnesretinainstitute.com ► Study: ASaP: Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration Sponsor: Potentia Pharmaceuticals, Inc. Information: federico@potentiapharma.com ► Study: A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD Sponsor: Oregon Health and Science University Information: (503) 494-3616 ► Study: CABERNET: Study of Strontium90 Beta Radiation With Lucentis to Treat AMD Sponsor: NeoVista Information: (510) 933-7650, info@neovistainc.com ► Study: Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1) Sponsor: Regeneron/Bayer Information: vegf.trap@regeneron.com ► Study: A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Sponsor: Jerini Ophthalmic Information: (919) 226-1440 ×325 ► Study: Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST) Sponsor: Retina Vitreous Associates, P.C.; Genentech Information: cawh@aol.com ► Study: A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD Sponsor: GlaxoSmithKline Information: (877) 379-3718 ► Study: Phase 1, Safety, Tolerability, and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration Sponsor: Ophthotech Corp. Information: denise.teuber@ophthotech.com ► Study: CATT: Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Sponsor: National Eye Institute Information: dan.martin@emory.edu ► Study: Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration Sponsor: National Eye Institute Information: (800) 411-1222 ► Study: The MAP Study: FA/Medidur for AMD Pilot Sponsor: Johns Hopkins University/Alimera Sciences Information: ghafiz1@jhmi.edu ► Study: Antioxidant Systems and Age-Related Macular Degeneration Sponsor: Vanderbilt University/National Institutes of Health Information: paul.sternberg@vanderbilt.edu ► Study: High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-Related Macular Degeneration Sponsor: National Eye Institute Information: prpl@mail.cc.nih.gov ► Study: ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration Sponsor: Ophthotech Corporation Information: dbeutelspacher@ophthotech.com ► Study: Reduced Fluence PDT With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Sponsor: Oklahoma State University Center for Health Sciences/Novartis Information: (918) 747-7799 ► Study: Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-Related Macular Degeneration (AMD) Sponsor: Lahey Clinic Information: Avon.P.Stewart@Lahey.org

WET AMD

► Study: A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
Sponsor: Genentech
Purpose: To study the efficacy and safety of ranibizumab injection administered intravitreally to patients with CNV secondary to AMD
Design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment
Number of Patients: 1100
Inclusion Criteria: For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study; CNV lesions with classic CNV component, occult CNV, or with some classic CNV component are permissible
Exclusion Criteria: History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye; prior treatment with Visudyne, external-beam radiation therapy, or TTT in the study eye; previous intravitreal drug delivery (eg, intravitreal corticosteroid injection, anti-angiogenic drugs, or device implantation) in the study eye; previous treatment or participation in a clinical trial involving antiangiogenic drugs (Avastin, anecortave acetate, protein kinase C inhibitors, etc.), in the non-study eye within 3 months of Day 0. The patient may not have received Lucentis or Macugen in the nonstudy eye within 7 days of Day 0; treatment with Visudyne in the non-study eye < 7 days preceding Day 0; subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either > 50% of the total area of the lesion or > 1 disc area (2.54 mm²) in size; subfoveal fibrosis or atrophy in the study eye; CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia; retinal pigment epithelial tear involving the macula in the study eye; any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could either: require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 24-month study period
Information: lane.hayley@gene.com

► Study: A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Sponsor: Ophthotech Corporation
Purpose: To evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)
Design: Treatment, Nonrandomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study
Number of Patients: 50
Inclusion Criteria: Subfoveal choroidal neovascularization (CNV) due to AMD (ie, predominantly classic, minimally classic or occult no classic) as documented by fluorescein angiogram
Exclusion Criteria: Any prior treatment for AMD or any intravitreal treatment for any indication in the study eye prior to the screening visit, except oral supplements of vitamins and minerals; previous or concomitant therapy with intravitreous corticosteroids; diabetic retinopathy; history or evidence of severe cardiac disease (eg, NYHA Functional Class III or IV - see Appendix 19.6); history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment; history or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation; clinically significant impaired renal (serum creatinine >2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. Patients with results outside these ranges may be enrolled in consultation with Ophthotech
Information: (212) 845-8214

► Study: Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
Sponsor: National Eye Institute
Purpose: To measure antibody levels in the blood of people with bleeding or swelling in the retina who have or have not been treated with bevacizumab or ranibizumab
Design: Prospective
Number of Patients: 30
Inclusion Criteria: Subjects will include adults being treated for exudative AMD, or macular edema secondary to DR or venous occlusion
Exclusion Criteria: Patients who are currently receiving any form of systemic immunosuppressive or immunomodulatory therapy, including corticosteroids; patients who have autoimmune or rheumatologic disease; patients with evidence of active systemic infection
Information: prpl@mail.cc.nih.gov

► Study: EMERALD: Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis in Patients With Age-Related Macular Degeneration
Sponsor: MacuSight, Inc.
Purpose: To determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Number of Patients: 60
Inclusion Criteria: Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration within 6 months of initial study visit, and may have been treated with up to 3 Lucentis (ranibizumab) or 3 Avastin (bevacizumab) injections with the last injection administered at least 4 weeks prior to the initial study visit, or is treatment-naïve; VA of 20/40 to 20/200 in the study eye
Exclusion Criteria: Any other ocular disease that could compromise vision in the study eye; presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration
Information: cdelpouys@macusight.com

► Study: ROSE: A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
Sponsor: NeoVista
Purpose: To evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age-related macular degeneration that have failed primary anti-VEGF therapy
Design: Treatment, Nonrandomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Number of Patients: 20
Inclusion Criteria: Subjects must have predominantly classic, minimally classic, or occult with no classic lesions, as determined by the Investigator, secondary to AMD, with a total lesion size (including blood, scarring, and neovascularization) of <12 total disc areas (21.24mm²), and a GLD ≥5.4 mm; subjects must have received a minimum of 3 prior injections (a minimum of 3 prior injections of the same compound) of anti-VEGF therapy (Lucentis or Avastin, subjects may have been treated previously with Macugen, but must have been most recently treated with Lucentis or Avastin and met the criteria for failure below) with evidence of "failure" to respond to therapy; subjects must be age 50 or older
Exclusion Criteria: Subjects with prior or subfoveal CNV therapy with photodynamic therapy, intravitreal or subretinal steroids, or transpupillary thermotherapy (TTT) (Note: This includes subjects with no known history, but with photographic evidence of prior therapy); subjects who underwent previous radiation therapy to the eye, head or neck; subjects who have been previously diagnosed with type 1 or type 2 diabetes mellitus. Subjects who do not have a documented diagnosis but have retinal findings consistent with type 1 or type 2 diabetes mellitus; women of child-bearing potential (female subjects must be postmenopausal or surgically sterilized)
Information: clinicaltrials@neovistainc.com

► Study: Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-Related Macular Degeneration
Sponsor: Lpath, Inc.
Purpose: To assess the safety of iSONEP, which is a humanized monoclonal antibody against a bioactive lipid, sphingosine 1-phosphate (S1P)
Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study
Number of Patients: 33
Inclusion Criteria: 50 years and older; BCVA ETDRS letter score in study eye between 20-57 letters using ETDRS refraction (Snellen of 20/70-20/400); any CNV secondary to AMD in study eye, classic, minimally classic or occult with leakage on fluorescein angiography and intraretinal or subretinal fluid on OCT; visual acuity in fellow eye must be 20/800 or better at 4 meters
Exclusion Criteria: Ocular disease other than CNV that could compromise vision in study eye; systemic immunosuppressive medication/therapy (eg, chemotherapy, steroids); uncontrolled hypertension and/or arrhythmias; QT/QTc interval measurement >450 milliseconds; cancer within the last 2 years except superficial basal or squamous cell skin cancer or cervical carcinoma in situ; have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (>8 D) or CNV secondary to other causes than AMD; any additional ocular diseases which have irreversibly compromised VA of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant DME and severe nonproliferative diabetic retinopathy; any intraocular or general surgery, including cataract surgery, within 2 months of Day 1; history of uveitis in either eye; any ocular or periocular infection within 4 weeks prior to Day 1; active ocular inflammation grade trace and above; cup to disc ratio >0.8, IOP >21 mm Hg in glaucoma subjects treated with more than 2 ocular hypotensive agents; previous pars plana vitrectomy or trabeculectomy in study eye; history of anterior vitrectomy; inability to obtain photographs, FA or OCT to document CNV, eg, due to media opacity, allergy to fluorescein dye, or lack of venous access; aphakia
Information: (270) 554-8929

► Study: Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Sponsor: Retina Macula Institute
Purpose: To assess 2 groups (monthly and PRN therapy) and assess high resolution OCT, microperimetry, and multifocal ERG outcomes
Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment
Number of Patients: 45
Inclusion Criteria: Age ≥50 years old; patients with active neovascular AMD
Exclusion Criteria: Participation in another simultaneous medical investigation or trial; concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); previous PDT therapy; previous intravitreal steroid therapy within last 3 months; previous anti-VEGF therapy in the past month
Information: lillian.rmi@gmail.com

► Study: Combination Ranibizumab and Bromfenac for Neovascular Age-Related Macular Degeneration
Sponsor: Oregon Health and Science University/Genentech
Purpose: To determine whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone
Design: Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Number of Patients: 30
Inclusion Criteria: Age >50 years; patients with active neovascular AMD; if the patient has bilateral disease and qualifies for the study, both eyes may be included
Exclusion Criteria: Concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); previous intravitreal steroid or anti-VEGF therapy within last 3 months; patients with a concurrent corneal epithelial disruption or erosion; patients with immune deficiencies that would affect the ability of the cornea to heal; patients with a known sensitivity to any component of the formulations under investigation
Information: schainm@ohsu.edu

► Study: ERG/EOG Study in AMD Patients Treated With Ranibizumab
Sponsor: Retina Center, Minnesota/Genentech
Purpose: To focus on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD
Design: Case-Only, Prospective
Number of Patients: 10
Inclusion Criteria: Patients to be included in the study must have AMD with choroidal neovascularization; BCVA between 20/20 and 20/400; lesion size ≤12 MPS disc areas
Exclusion Criteria: Media insufficient to obtain a view; other causes of CNV not related to AMD; active ocular or periocular infection; ocular surgery within 1 month prior to the study; any other condition the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated; participation in another simultaneous medical investigation or trial; media insufficient to obtain a view; other causes of CNV not related to AMD
Information: vu@retinadocs.com

► Study: Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Sponsor: OSI/Pfizer
Information: (866) 622-8436

► Study: LUV: Lucentis Utilizing Visudyne Combination Therapy in the Treatment of Age-Related Macular Degeneration
Sponsor: Novartis/Greater Houston Retinal Research
Information: http://www.houstonretina.com/

► Study: A Phase I Trial of a Single Intravitreal Injection of REDD14NP to Patients With CNV Secondary to Wet AMD
Sponsor: Quark Biotech, Inc.
Information: (212) 452-6902

► Study: Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced-Fluence PDT in Patients With Wet AMD
Sponsor: Barnes Retina Institute
Information: bristudies@barnesretinainstitute.com

► Study: ASaP: Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration
Sponsor: Potentia Pharmaceuticals, Inc.
Information: federico@potentiapharma.com

► Study: A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
Sponsor: Oregon Health and Science University
Information: (503) 494-3616

► Study: CABERNET: Study of Strontium90 Beta Radiation With Lucentis to Treat AMD
Sponsor: NeoVista
Information: (510) 933-7650, info@neovistainc.com

► Study: Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1)
Sponsor: Regeneron/Bayer
Information: vegf.trap@regeneron.com

► Study: A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
Sponsor: Jerini Ophthalmic
Information: (919) 226-1440 ×325

► Study: Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST)
Sponsor: Retina Vitreous Associates, P.C.; Genentech
Information: cawh@aol.com

► Study: A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
Sponsor: GlaxoSmithKline
Information: (877) 379-3718

► Study: Phase 1, Safety, Tolerability, and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
Sponsor: Ophthotech Corp.
Information: denise.teuber@ophthotech.com

► Study: CATT: Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
Sponsor: National Eye Institute
Information: dan.martin@emory.edu

► Study: Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Sponsor: National Eye Institute
Information: (800) 411-1222

► Study: The MAP Study: FA/Medidur for AMD Pilot
Sponsor: Johns Hopkins University/Alimera Sciences
Information: ghafiz1@jhmi.edu

► Study: Antioxidant Systems and Age-Related Macular Degeneration
Sponsor: Vanderbilt University/National Institutes of Health
Information: paul.sternberg@vanderbilt.edu

► Study: High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-Related Macular Degeneration
Sponsor: National Eye Institute
Information: prpl@mail.cc.nih.gov

► Study: ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
Sponsor: Ophthotech Corporation
Information: dbeutelspacher@ophthotech.com

► Study: Reduced Fluence PDT With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
Sponsor: Oklahoma State University Center for Health Sciences/Novartis
Information: (918) 747-7799

► Study: Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-Related Macular Degeneration (AMD)
Sponsor: Lahey Clinic
Information: Avon.P.Stewart@Lahey.org

RETINAL IMAGING STUDIES
► Study: Retinal Imaging in Patients With Inherited Retinal Degenerations Sponsor: University of California-San Francisco/University of California-Berkeley Status: Enrolling patients Purpose: To determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope Design: Natural History, Longitudinal, Defined Population, Prospective Study Number of Patients: 130 Inclusion Criteria: Subjects must have pupils that dilate to at least 6 mm diameter and must be willing to travel to UC Berkeley Exclusion Criteria: Cataract; irregular corneal astigmatism (keratoconus); prior refractive surgery Information: Jacque L. Duncan, MD, (415) 514-4241, duncanj@vision.ucsf.edu ► Study: Novel Diagnostics for Ocular Structure Sponsor: University of Pittsburgh/National Institutes of Health Status: Enrolling patients Purpose: To evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called OCT Design: Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study Number of Patients: 500 Inclusion Criteria: Diagnosis of macular degeneration, diabetic retinopathy, and/or glaucoma Exclusion Criteria: Media opacity (lens, vitreous, cornea); diagnosis of strabismus, nystagmus, or a condition that would prevent fixation Information: Tammy J Capozzoli, (412) 647-2375, capozzolitj@upmc.edu ► Study: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging Sponsor: University of Pittsburgh Status: Currently enrolling Purpose: To evaluate OCT, an FDA-approved device used to image diseases of the eye Design: Screening, Longitudinal, Convenience Sample, Retrospective/Prospective Study Number of Patients: 1500 Inclusion Criteria: Subjects with healthy eyes, macular degeneration, glaucoma and various other eye diseases. Also must be able to fixate on target. Exclusion Criteria: Fundus not visible or opaque media Information: (412) 647-2375 ► Study: Metabolic Mapping to Measure Retinal Metabolism Sponsor: National Eye Institute Status: Currently enrolling Information: (800) 411-1222

RETINAL IMAGING STUDIES

► Study: Retinal Imaging in Patients With Inherited Retinal Degenerations
Sponsor: University of California-San Francisco/University of California-Berkeley
Status: Enrolling patients
Purpose: To determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope
Design: Natural History, Longitudinal, Defined Population, Prospective Study
Number of Patients: 130
Inclusion Criteria: Subjects must have pupils that dilate to at least 6 mm diameter and must be willing to travel to UC Berkeley
Exclusion Criteria: Cataract; irregular corneal astigmatism (keratoconus); prior refractive surgery
Information: Jacque L. Duncan, MD, (415) 514-4241, duncanj@vision.ucsf.edu

► Study: Novel Diagnostics for Ocular Structure
Sponsor: University of Pittsburgh/National Institutes of Health Status: Enrolling patients
Purpose: To evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called OCT
Design: Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study
Number of Patients: 500
Inclusion Criteria: Diagnosis of macular degeneration, diabetic retinopathy, and/or glaucoma
Exclusion Criteria: Media opacity (lens, vitreous, cornea); diagnosis of strabismus, nystagmus, or a condition that would prevent fixation
Information: Tammy J Capozzoli, (412) 647-2375, capozzolitj@upmc.edu

► Study: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging
Sponsor: University of Pittsburgh
Status: Currently enrolling
Purpose: To evaluate OCT, an FDA-approved device used to image diseases of the eye
Design: Screening, Longitudinal, Convenience Sample, Retrospective/Prospective Study
Number of Patients: 1500
Inclusion Criteria: Subjects with healthy eyes, macular degeneration, glaucoma and various other eye diseases. Also must be able to fixate on target.
Exclusion Criteria: Fundus not visible or opaque media
Information: (412) 647-2375

► Study: Metabolic Mapping to Measure Retinal Metabolism
Sponsor: National Eye Institute
Status: Currently enrolling
Information: (800) 411-1222

DIABETIC MACULAR EDEMA
► Study: Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema Sponsor: iCo Therapeutics Inc. Purpose: To evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse DME Design: Treatment, Open Label, Single Group Assignment, Safety Study Number of Patients: 15 Inclusion Criteria: Confirmed diagnosis of diabetes mellitus type 1 or 2 (both, insulin or non-insulin dependent); subjects who have moderate to severe non-proliferative diabetic retinopathy (NPDR), as defined by ETDRS criteria, and diffuse DME within 300 μm from the center of the macula in the study eye (with or without cystoid changes) confirmed by FA; retinal thickness must be at least 250 μm in the central subfield, as shown by OCT; BCVA between 60 and 15 letters measured with ETDRS charts (approximately 20/63 to 20/500 with Snellen charts) Exclusion Criteria: Subjects with macular or perimacular edema secondary to an etiology other than diabetes mellitus; subjects with concurrent retinal diseases or conditions in the study eye (including conditions requiring urgent PRP), glaucoma or ocular hypertension), retinal vascular occlusion, exudative AMD (drusen permitted), tear (rip) of the RPE, a vitelliform-like lesion of the outer retina (eg, pattern dystrophies or basal laminar drusen), idiopathic parafoveal telangiectasis or retinal-lesion anastomosis; subjects who have any additional ocular disease or condition which could compromise treatment safety, VA or interfere with assessment of the macular edema, such as ocular inflammation, amblyopia, anterior ischemic optic neuropathy, media opacity, cataract; subjects who have diffuse DME with severe capillary non-perfusion (avascular zone diameter >1000 μm); allergy to fluorescein dye; subjects who had intraocular surgery, photocoagulation, intravitreal or subfoveal injection, topical or systemic steroids or who received any experimental treatment as part of another clinical trial within the last 3 months of the study start (in case of anecortave within the last 6 months, any panretinal photocoagulation prior to study start); subjects with uncontrolled diabetes (glycosylated hemoglobin Hb A1c >12%); subjects with systolic blood pressure higher than 180 mm Hg or diastolic above 100 mm Hg, with or without anti-hypertensive treatment; subjects with congestive heart disease or any unstable cardiac condition; subjects with clinically significantly impaired renal function (serum creatinine >2.0 mg/dL) and/or moderate to severe hepatic impairment (subjects with >2.5 times the upper limit of the normal range for aspartate transaminase [AST], alanine transaminase [ALT], or total bilirubin) Information: nidia.rosado@duke.edu ► Study: A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients Sponsor: Alcon Research Purpose: To determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients Design: Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment Number of Patients: 260 Inclusion Criteria: Patients with nonproliferative diabetic retinopathy (mild, moderate or severe) and planned cataract extraction by phacoemulsification Exclusion Criteria: Central subfiled macular thickness >250 μm; CME in either eye Information: (888) 451-3937 ► Study: Near-Infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study Sponsor: Medical College of Wisconsin Purpose: To examine the use of NIR because it has been approved as a nonsignificant risk (NSR) device for treatment of eye disorders, it has a low cost of treatment, and it may serve as an effective, noninvasive alternative or adjunctive treatment to laser photocoagulation, the current standard of care for DME Design: Nonrandomized, Open Label, Safety/Efficacy Study, Single Group Assignment, Treatment Number of Patients: 20 Inclusion Criteria: Age ≥18 years Subjects <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable; diagnosis of diabetes mellitus (type 1 or type 2); at least 1 eye meets the study eye criteria; fellow eye meets criteria; any candidate identified by a study investigator as being able to successfully tolerate a 3-month deferral of laser photocoagulation Exclusion Criteria: Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant; subjects in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled; participation in an investigational trial within 30 days of NIR participation that involved treatment with any drug that has not received regulatory approval at the time of study entry; major surgery within 28 days prior to participation or major surgery planned during the next 6 months Information: hwhelan@mcw.edu ► Study: DA VINCI: DME And VEGF Trap-Eye: INvestigation of Clinical Impact Sponsor: Regeneron Pharmaceuticals/Bayer Purpose: To study of efficacy and safety of VEGF Trap-Eye in subjects with diabetic macular edema Design: Active Control, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Randomized, Safety/Efficacy Study, Treatment Number of Patients: 200 Inclusion Criteria: Patients with clinically significant DME with central involvement; adults 18 years or older with type 1 or 2 diabetes mellitus with diabetic macular edema; ETDRS BCVA: 20/40 to 20/320 (letter score of 73 to 24) in the study eye Exclusion Criteria: History of vitreoretinal surgery in the study eye; panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening; previous use of intraocular or periocular corticosteroids in the study eye within 3 months of screening; previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of screening; uncontrolled diabetes mellitus; uncontrolled hypertension defined as systolic >180 mm Hg or >160 mm Hg on 2 consecutive measurements or diastolic >100 mm Hg on optimal medical regimen; ocular disorders in the study eye, other than DME, that may confound interpretation of study results Information: maria.thurman@parexel.com ► Study: Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema Sponsor: Allergan Purpose: To evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with DME Design: Nonrandomized, Open Label, Safety/Efficacy Study, Single Group Assignment, Treatment Number of Patients: 40 Inclusion Criteria: 18 years of age or older with DME, history of vitrectomy, central retinal thickness ≥275 μm, VA between 20/320 and 20/40 in the study eye and no worse than 20/200 in the other eye Exclusion Criteria: Known anticipated need for ocular surgery during the study period, history of glaucoma or current high eye pressure requiring more than 1 medication, uncontrolled systemic disease, known allergy to the study medication, known steroid-responder, use of systemic steroids, female subjects that are pregnant, nursing or planning a pregnancy Information: clinicaltrials@allergan.com ► Study: Study Comparing Two Doses of Ranibizumab in the Treatment of Clinically Significant Diabetic Macular Edema Sponsor: Long Island Vitreoretinal Consultants Purpose: To evaluate the safety and tolerability of ranibizumab in patients with clinically significant diabetic macular edema (CSDME). It will also compare treatment outcomes for patients receiving 0.5 mg ranibizumab to those receiving 1.0 mg ranibizumab Design: Treatment, Randomized, Single Blind (Subject), Dose Comparison, Parallel Assignment, Safety/Efficacy Study Number of Patients: 50 Inclusion Criteria: Type 1 or Type 2 diabetic subjects; vision between 20/20 and 20/400; presence of CSDME Exclusion Criteria: Presence of any condition that would prevent clear visualization of the back of the eye; uncontrolled glaucoma; inflammation inside the eye; certain prior eye surgeries, other than cataract surgery; other eye diseases that may compromise the vision in the study eye Information: mschlameuss@longislandretina.com ► Study: Study of the Safety and Efficacy of a New Treatment for DME Sponsor: Allergan Information: clinicaltrials@allergan.com ► Study: Effect of Ruboxistaurin on Clinically Significant Macular Edema Sponsor: Eli Lilly and Company Information: (877) 285-4559 ► Study: Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Sponsor: NEI/Genentech/Allergan Information: (866) 372-7601 ► Study: A Study of the Safety and Efficacy of a New Treatment in Combination With Laser for Macular Edema Resulting From DME Sponsor: Allergan Information: clinicaltrials@allergan.com ► Study: Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy Sponsor: Novagali Pharma mourad.amrane@novagali.com ► Study: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II) Sponsor: Genentech/Michael J. Jumper Information: jrose@westcoastretina.com ► Study: Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV) (ITVR) Sponsor: Retina Research Foundation Information: (518) 533-6550 ► Study: Sirolimus to Treat DME Sponsor: National Eye Institute Information: (800) 411-1222 ► Study: DEGAS: Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With DME Sponsor: Pfizer Information: (800) 718-1021 ► Study: Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of DME Sponsor: Bp Consulting, Inc. Information: michelle-bpconsulting@yahoo.com

DIABETIC MACULAR EDEMA

► Study: Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
Sponsor: iCo Therapeutics Inc.
Purpose: To evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse DME
Design: Treatment, Open Label, Single Group Assignment, Safety Study
Number of Patients: 15
Inclusion Criteria: Confirmed diagnosis of diabetes mellitus type 1 or 2 (both, insulin or non-insulin dependent); subjects who have moderate to severe non-proliferative diabetic retinopathy (NPDR), as defined by ETDRS criteria, and diffuse DME within 300 μm from the center of the macula in the study eye (with or without cystoid changes) confirmed by FA; retinal thickness must be at least 250 μm in the central subfield, as shown by OCT; BCVA between 60 and 15 letters measured with ETDRS charts (approximately 20/63 to 20/500 with Snellen charts)
Exclusion Criteria: Subjects with macular or perimacular edema secondary to an etiology other than diabetes mellitus; subjects with concurrent retinal diseases or conditions in the study eye (including conditions requiring urgent PRP), glaucoma or ocular hypertension), retinal vascular occlusion, exudative AMD (drusen permitted), tear (rip) of the RPE, a vitelliform-like lesion of the outer retina (eg, pattern dystrophies or basal laminar drusen), idiopathic parafoveal telangiectasis or retinal-lesion anastomosis; subjects who have any additional ocular disease or condition which could compromise treatment safety, VA or interfere with assessment of the macular edema, such as ocular inflammation, amblyopia, anterior ischemic optic neuropathy, media opacity, cataract; subjects who have diffuse DME with severe capillary non-perfusion (avascular zone diameter >1000 μm); allergy to fluorescein dye; subjects who had intraocular surgery, photocoagulation, intravitreal or subfoveal injection, topical or systemic steroids or who received any experimental treatment as part of another clinical trial within the last 3 months of the study start (in case of anecortave within the last 6 months, any panretinal photocoagulation prior to study start); subjects with uncontrolled diabetes (glycosylated hemoglobin Hb A1c >12%); subjects with systolic blood pressure higher than 180 mm Hg or diastolic above 100 mm Hg, with or without anti-hypertensive treatment; subjects with congestive heart disease or any unstable cardiac condition; subjects with clinically significantly impaired renal function (serum creatinine >2.0 mg/dL) and/or moderate to severe hepatic impairment (subjects with >2.5 times the upper limit of the normal range for aspartate transaminase [AST], alanine transaminase [ALT], or total bilirubin)
Information: nidia.rosado@duke.edu

► Study: A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Sponsor: Alcon Research
Purpose: To determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients
Design: Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Number of Patients: 260
Inclusion Criteria: Patients with nonproliferative diabetic retinopathy (mild, moderate or severe) and planned cataract extraction by phacoemulsification
Exclusion Criteria: Central subfiled macular thickness >250 μm; CME in either eye
Information: (888) 451-3937

► Study: Near-Infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study
Sponsor: Medical College of Wisconsin
Purpose: To examine the use of NIR because it has been approved as a nonsignificant risk (NSR) device for treatment of eye disorders, it has a low cost of treatment, and it may serve as an effective, noninvasive alternative or adjunctive treatment to laser photocoagulation, the current standard of care for DME
Design: Nonrandomized, Open Label, Safety/Efficacy Study, Single Group Assignment, Treatment
Number of Patients: 20
Inclusion Criteria: Age ≥18 years Subjects <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable; diagnosis of diabetes mellitus (type 1 or type 2); at least 1 eye meets the study eye criteria; fellow eye meets criteria; any candidate identified by a study investigator as being able to successfully tolerate a 3-month deferral of laser photocoagulation
Exclusion Criteria: Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant; subjects in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled; participation in an investigational trial within 30 days of NIR participation that involved treatment with any drug that has not received regulatory approval at the time of study entry; major surgery within 28 days prior to participation or major surgery planned during the next 6 months
Information: hwhelan@mcw.edu

► Study: DA VINCI: DME And VEGF Trap-Eye: INvestigation of Clinical Impact
Sponsor: Regeneron Pharmaceuticals/Bayer
Purpose: To study of efficacy and safety of VEGF Trap-Eye in subjects with diabetic macular edema
Design: Active Control, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Randomized, Safety/Efficacy Study, Treatment
Number of Patients: 200
Inclusion Criteria: Patients with clinically significant DME with central involvement; adults 18 years or older with type 1 or 2 diabetes mellitus with diabetic macular edema; ETDRS BCVA: 20/40 to 20/320 (letter score of 73 to 24) in the study eye
Exclusion Criteria: History of vitreoretinal surgery in the study eye; panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening; previous use of intraocular or periocular corticosteroids in the study eye within 3 months of screening; previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of screening; uncontrolled diabetes mellitus; uncontrolled hypertension defined as systolic >180 mm Hg or >160 mm Hg on 2 consecutive measurements or diastolic >100 mm Hg on optimal medical regimen; ocular disorders in the study eye, other than DME, that may confound interpretation of study results
Information: maria.thurman@parexel.com

► Study: Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
Sponsor: Allergan
Purpose: To evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with DME
Design: Nonrandomized, Open Label, Safety/Efficacy Study, Single Group Assignment, Treatment
Number of Patients: 40
Inclusion Criteria: 18 years of age or older with DME, history of vitrectomy, central retinal thickness ≥275 μm, VA between 20/320 and 20/40 in the study eye and no worse than 20/200 in the other eye
Exclusion Criteria: Known anticipated need for ocular surgery during the study period, history of glaucoma or current high eye pressure requiring more than 1 medication, uncontrolled systemic disease, known allergy to the study medication, known steroid-responder, use of systemic steroids, female subjects that are pregnant, nursing or planning a pregnancy
Information: clinicaltrials@allergan.com

► Study: Study Comparing Two Doses of Ranibizumab in the Treatment of Clinically Significant Diabetic Macular Edema
Sponsor: Long Island Vitreoretinal Consultants
Purpose: To evaluate the safety and tolerability of ranibizumab in patients with clinically significant diabetic macular edema (CSDME). It will also compare treatment outcomes for patients receiving 0.5 mg ranibizumab to those receiving 1.0 mg ranibizumab
Design: Treatment, Randomized, Single Blind (Subject), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Number of Patients: 50
Inclusion Criteria: Type 1 or Type 2 diabetic subjects; vision between 20/20 and 20/400; presence of CSDME
Exclusion Criteria: Presence of any condition that would prevent clear visualization of the back of the eye; uncontrolled glaucoma; inflammation inside the eye; certain prior eye surgeries, other than cataract surgery; other eye diseases that may compromise the vision in the study eye
Information: mschlameuss@longislandretina.com

► Study: Study of the Safety and Efficacy of a New Treatment for DME
Sponsor: Allergan
Information: clinicaltrials@allergan.com

► Study: Effect of Ruboxistaurin on Clinically Significant Macular Edema
Sponsor: Eli Lilly and Company
Information: (877) 285-4559

► Study: Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Sponsor: NEI/Genentech/Allergan
Information: (866) 372-7601

► Study: A Study of the Safety and Efficacy of a New Treatment in Combination With Laser for Macular Edema Resulting From DME
Sponsor: Allergan
Information: clinicaltrials@allergan.com

► Study: Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Sponsor: Novagali Pharma mourad.amrane@novagali.com

► Study: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
Sponsor: Genentech/Michael J. Jumper
Information: jrose@westcoastretina.com

► Study: Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV) (ITVR)
Sponsor: Retina Research Foundation
Information: (518) 533-6550

► Study: Sirolimus to Treat DME
Sponsor: National Eye Institute
Information: (800) 411-1222

► Study: DEGAS: Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With DME
Sponsor: Pfizer
Information: (800) 718-1021

► Study: Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of DME
Sponsor: Bp Consulting, Inc.
Information: michelle-bpconsulting@yahoo.com

RETINAL VEIN OCCLUSION
► Study: Effectiveness and Safety of Niacin and a Topical Steroid to Treat Retinal Vein Occlusions Sponsor: Palo Alto Medical Foundation Status: Currently enrolling Purpose: To determine whether niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye Design: Treatment, Nonrandomized, Open-label, Active-control, Single-group Assignment, Safety/Efficacy Study Number of Patients: 68 Inclusion Criteria: Patient must have central retinal vein occlusion, hemi-retinal vein occlusion or branch retinal vein occlusion Exclusion Criteria: Active gout or high levels of uric acid Information: gaynonM@pamf.org ► Study: Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Sponsor: Palmetto Retina Center, LLC; Pfizer; OSI Pharmaceuticals Status: Currently enrolling Purpose: Study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO) Design: Treatment, Randomized, Open-label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study Number of Patients: 30 Inclusion Criteria: Macular edema secondary to BRVO involving the foveal center in male or female patients at least 18 years of age; duration of BRVO macular edema less than 6 months prior to baseline visit; best corrected ETDRS VA 20/40 to 20/320 (Snellen equivalent) using the 4 meters testing method; central foveal thickness ≥250 μm using the OCT-3; <25% of foveal capillary ring disruption; <2 disc areas of capillary nonperfusion within 1000 μm of the foveal center; absence of hemorrhage or lipid in the foveal center Exclusion Criteria: Ocular conditions other than BRVO-related macular edema such as significant cataract, diabetic retinopathy, AMD, glaucoma, uveitis, epiretinal membrane, vitreomacular traction or tumor; intraocular surgery within past 3 months; significant enlargement of foveal avascular zone(>25% disruption of capillary ring) or greater than 2 disc areas of nonperfusion within 1000 μm of foveal center; likelihood of evidence-driven indication for peripheral photocoagulation in the next 6 months; patients who have shown evidence of spontaneous improvement within the preceding 3 months, as determined by an improvement of >15 letters of vision or thinning of the center point on OCT of >20% from baseline determination; prior grid laser within 4 months of baseline or more than 1 prior grid laser treatment; no prior intravitreous or periocular steroid injections in the study eye Information: jackwells@palmettoretina.com ► Study: Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) Sponsor: Duke University; Bausch & Lomb Status: Currently enrolling Purpose: To determine whether a fluocinolone acetonide sustained drug delivery implant is effective in the treatment of retinal vein occlusion that has caused persistent macular edema and decreased visual acuity Design: Treatment, Nonrandomized, Open-label, Uncontrolled, Single-group Assignment, Safety/Efficacy Study Number of Patients: 30 Inclusion Criteria: A history of retinal vein occlusion that had caused macular edema, based on clinical evaluation and demonstrated on fundus photography, fluorescein angiography, and OCT; macular edema at least 1 disc area in size that involved the fovea; males and nonpregnant females at least 18 years of age; IOP controlled at <21 mm Hg with no more than 1 topical ocular antihypertensive agent; initially, patients with vein occlusion were not required to have previous therapy. However, the protocol was subsequently modified to require an intravitreal injection of triamcinolone acetonide >12 weeks prior to study entry, with an initial decrease in macular edema and improvement in VA and subsequent decline in VA accompanied by increased macular edema. This modification was added to avoid enrolling patients who might have had a long-lasting response to a single intravitreal triamcinolone acetonide injection Exclusion Criteria: Patients are excluded if they have an allergy to fluocinolone acetonide or any component of the delivery system, a peripheral retinal detachment in the area of implantation, or media opacity precluding evaluation of study eye status; patients with disciform scars of the fovea or atrophic changes of the macula that in the investigator's opinion would preclude benefit from treatment are excluded from the study; female patients who were pregnant or lactating or not taking precautions to avoid pregnancy Information: (919) 684-4458 ► Study: Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema Sponsor: Vitreous-Retina Macula Consultants of New York/Genentech Status: Enrolling patients Purpose: To examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema Design: Treatment, Nonrandomized, Open-label, Active-control, Single-group Assignment, Safety Study Number of Patients: 45 Inclusion Criteria: Age >18 years; clinical evidence of perfused central retinal vein occlusion. A central retinal vein occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head; central macular edema present on clinical examination and OCT testing with a central point thickness >250 μm; visual acuity score greater than or equal to 34 letters (20/200) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol; media clarity, pupillary dilation, and patient cooperation sufficient to allow OCT testing and retinal photography Exclusion Critieria: Participation in another simultaneous ocular investigation or trial; uncontrolled hypertension; a condition that, in the opinion of the investigator would preclude participation in the study (ie, chronic alcoholism, drug abuse); significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy; exam or OCT reveals evidence of vitreoretinal interface abnormality that may be contributing to the macular edema; eye that in the investigator has no chance of improvement in visual acuity following resolution of macular edema (ie, subretinal fibrosis or geographic atrophy); any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), AMD, retinal detachment, severe cataracts, etc. Information: (212) 452-6965 ► Study: RAVE: Rubeosis Anti-VEGF Trial for Ischemic Central Retinal Vein Occlusion Sponsor: Greater Houston Retina Research Information: (713) 524-3434

RETINAL VEIN OCCLUSION

► Study: Effectiveness and Safety of Niacin and a Topical Steroid to Treat Retinal Vein Occlusions
Sponsor: Palo Alto Medical Foundation
Status: Currently enrolling
Purpose: To determine whether niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye
Design: Treatment, Nonrandomized, Open-label, Active-control, Single-group Assignment, Safety/Efficacy Study
Number of Patients: 68
Inclusion Criteria: Patient must have central retinal vein occlusion, hemi-retinal vein occlusion or branch retinal vein occlusion
Exclusion Criteria: Active gout or high levels of uric acid
Information: gaynonM@pamf.org

► Study: Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Sponsor: Palmetto Retina Center, LLC; Pfizer; OSI Pharmaceuticals
Status: Currently enrolling
Purpose: Study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO)
Design: Treatment, Randomized, Open-label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Number of Patients: 30
Inclusion Criteria: Macular edema secondary to BRVO involving the foveal center in male or female patients at least 18 years of age; duration of BRVO macular edema less than 6 months prior to baseline visit; best corrected ETDRS VA 20/40 to 20/320 (Snellen equivalent) using the 4 meters testing method; central foveal thickness ≥250 μm using the OCT-3; <25% of foveal capillary ring disruption; <2 disc areas of capillary nonperfusion within 1000 μm of the foveal center; absence of hemorrhage or lipid in the foveal center
Exclusion Criteria: Ocular conditions other than BRVO-related macular edema such as significant cataract, diabetic retinopathy, AMD, glaucoma, uveitis, epiretinal membrane, vitreomacular traction or tumor; intraocular surgery within past 3 months; significant enlargement of foveal avascular zone(>25% disruption of capillary ring) or greater than 2 disc areas of nonperfusion within 1000 μm of foveal center; likelihood of evidence-driven indication for peripheral photocoagulation in the next 6 months; patients who have shown evidence of spontaneous improvement within the preceding 3 months, as determined by an improvement of >15 letters of vision or thinning of the center point on OCT of >20% from baseline determination; prior grid laser within 4 months of baseline or more than 1 prior grid laser treatment; no prior intravitreous or periocular steroid injections in the study eye
Information: jackwells@palmettoretina.com

► Study: Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)
Sponsor: Duke University; Bausch & Lomb
Status: Currently enrolling
Purpose: To determine whether a fluocinolone acetonide sustained drug delivery implant is effective in the treatment of retinal vein occlusion that has caused persistent macular edema and decreased visual acuity
Design: Treatment, Nonrandomized, Open-label, Uncontrolled, Single-group Assignment, Safety/Efficacy Study
Number of Patients: 30
Inclusion Criteria: A history of retinal vein occlusion that had caused macular edema, based on clinical evaluation and demonstrated on fundus photography, fluorescein angiography, and OCT; macular edema at least 1 disc area in size that involved the fovea; males and nonpregnant females at least 18 years of age; IOP controlled at <21 mm Hg with no more than 1 topical ocular antihypertensive agent; initially, patients with vein occlusion were not required to have previous therapy. However, the protocol was subsequently modified to require an intravitreal injection of triamcinolone acetonide >12 weeks prior to study entry, with an initial decrease in macular edema and improvement in VA and subsequent decline in VA accompanied by increased macular edema. This modification was added to avoid enrolling patients who might have had a long-lasting response to a single intravitreal triamcinolone acetonide injection
Exclusion Criteria: Patients are excluded if they have an allergy to fluocinolone acetonide or any component of the delivery system, a peripheral retinal detachment in the area of implantation, or media opacity precluding evaluation of study eye status; patients with disciform scars of the fovea or atrophic changes of the macula that in the investigator's opinion would preclude benefit from treatment are excluded from the study; female patients who were pregnant or lactating or not taking precautions to avoid pregnancy
Information: (919) 684-4458

► Study: Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Sponsor: Vitreous-Retina Macula Consultants of New York/Genentech
Status: Enrolling patients
Purpose: To examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
Design: Treatment, Nonrandomized, Open-label, Active-control, Single-group Assignment, Safety Study
Number of Patients: 45
Inclusion Criteria: Age >18 years; clinical evidence of perfused central retinal vein occlusion. A central retinal vein occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head; central macular edema present on clinical examination and OCT testing with a central point thickness >250 μm; visual acuity score greater than or equal to 34 letters (20/200) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol; media clarity, pupillary dilation, and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Critieria: Participation in another simultaneous ocular investigation or trial; uncontrolled hypertension; a condition that, in the opinion of the investigator would preclude participation in the study (ie, chronic alcoholism, drug abuse); significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy; exam or OCT reveals evidence of vitreoretinal interface abnormality that may be contributing to the macular edema; eye that in the investigator has no chance of improvement in visual acuity following resolution of macular edema (ie, subretinal fibrosis or geographic atrophy); any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), AMD, retinal detachment, severe cataracts, etc.
Information: (212) 452-6965

► Study: RAVE: Rubeosis Anti-VEGF Trial for Ischemic Central Retinal Vein Occlusion
Sponsor: Greater Houston Retina Research
Information: (713) 524-3434

UVEITIS
► Study: Pegaptanib Therapy in Uveitis Sponsor: Wake Forest University Purpose: To evaluate the utility of pegaptanib in CME associated with noninfectious intermediate and panuveitis Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study Number of Patients: 5 Inclusion Criteria: Demonstrable (FA and/or OCT) bilateral or unilateral CME associated with uveitis of greater than 3 months but less than 1 years duration that is documented by 2 independent qualified observers; BCVA between 20/40 and 20/200 as measured by the ETDRS chart attributable to CME in the study eye; patients may be receiving systemic therapy for the treatment of their intraocular inflammation or CME, or may have been treated for the CME in the past; anterior chamber inflammation equal to or less than 1+ and vitreous inflammation equal to or less than 1+ cell and 1+ haze as per the ‘Standardization of Uveitis’ working group definition Exclusion Criteria: Allergy to pegaptanib or any of its components; diabetic retinopathy, macular degeneration, or any other ocular condition affecting the study eye that may cause vision loss or in the opinion of the study investigator would interfere with the evaluation of the efficacy of Macugen for the treatment of uveitis associated CME; suspicion/proved history or current diagnosis, (clinical or otherwise) of infectious uveitis; need for intraocular surgery within 30 weeks of study duration; periocular steroids to the study eye less than 6 weeks prior to study enrollment; history of any prior intravitreal injections in study eye; systemic immunomodulatory agent(s) added or increased in dosage (>20%) within the last 2 months prior to study enrollment, or potential need for any increase during the study; requirement for systemic corticosteroids in the equivalent of oral prednisone >30mg/day Information: lcooke@wfubmc.edu ► Study: Uveitis Gene-expression Profiling Sponsor: Oregon Health and Science University Purpose:To quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40000 gene sequences using microarray gene chip technology Design: Case Control, Prospective Number of Patients: 392 Exclusion Criteria: Special/vunerable subject populations (eg, mentally impaired persons and children) will not be enrolled Information: rosenbaj@ohsu.edu ► Study: Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Sponsor: Duke University/Childhood Arthritis and Rheumatology Research Alliance Purpose: To examine the efficacy of infliximab for the treatment of persistent uveitis in children Design: Active Control, Efficacy Study, Open Label, Parallel Assignment, Randomized, Treatment Number of Patients: 40 Inclusion Criteria: Ages 4 to 18 years old; noninfectious uveitis; persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications; failure of at least 6 weeks of treatment with a nonbiological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine; ability to provide informed consent (subject or parent/guardian); onset of uveitis <16 years of age; topical ophthalmologic treatments allowed; systemic corticosteroid use at entry may be allowed; willingness to use acceptable contraception if sexually active for the duration of the study and for 6 months after receiving the last infliximab infusion; concomitant methotrexate must be taken at time of initiation of infliximab; participant must be able to cooperate for a nonsedated slit lamp exam and visual acuity examination; negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab Exclusion Criteria: Previous use of biologic medications for uveitis; intraocular steroid injection or ophthalmologic surgery within the preceding 3 months; uveitis due to trauma or intraocular surgery; females who are pregnant, nursing, or planning pregnancy within 6 months after the last infliximab infusion; males who plan on fathering a child within 6 months after their last infliximab infusion; history of a known allergy to murine products; documentation of seropositivity for human immunodeficiency virus (HIV); documentation of a positive test for hepatitis B surface antigen or hepatitis C; known history of a serious infection (eg, hepatitis, pneumonia, or pyelonephritis) in the previous 3 months; opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening Information: (919) 684-6575 ► Study: Adalimumab (Humira) in the Treatment of Refractory Non-Infectious Uveitis Sponsor: Oregon Health and Science University Purpose: To assess the safety and efficacy of adalimumab in uveitis Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study Number of Patients: Unavailable Inclusion Criteria: Patients with vision-threatening autoimmune uveitis; failure to respond to prednisone and at least 1 other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects Exclusion Criteria: Serious concomitant illness that could interfere with the subject's participation in the trial; previous or current use of cyclophosphamide; unable or unwilling to undergo multiple injections Information: suhlere@ohsu.edu ► Study: Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema Sponsor: University of Miami/Genentech Purpose: To determine if an anti-VEGF agent, Lucentis, is safe and effective in leading to regression of macular edema due to chronic noninfectious uveitis in patients with well-controlled uveitis Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Number of Patients: 10 Inclusion Criteria: Ability to provide written informed consent and comply with study assessments for the full duration of the study; age >18 years; noninfectious uveitis in study eye; stable anti-uveitis medical regimen for at least 1 month prior to injection and controlled uveitis in the judgment of the investigator; vision 20/40 or worse in study eye; CME on fluorescein angiography (FA); OCT demonstrating thickness greater than 300 μm in the central subfield; media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography Exclusion Criteria: Previous intravitreal triamcinolone injection in study eye within 3 months of study injection; use of more than 2 glaucoma medicines for study eye; significant epiretinal membrane as judged by treating physician; evidence of vitreomacular traction on OCT; previous vitrectomy in study eye; pregnancy (positive pregnancy test) or lactation; premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch; any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated; participation in another simultaneous IND trial; treatment for CME with intravitreal Lucentis, Macugen, or Avastin within 6 weeks prior to enrollment in this study Information: talbini@med.miami.edu ► Study: Immune Responses to Antigens in Noninfectious Eye Inflammatory Diseases Sponsor: National Eye Institute Information: (800) 411-1222 ► Study: Quality of Life and Visual Function in Uveitis Patients Sponsor: New York Eye and Ear Infirmar Information: (212) 979-4251 ► Study: Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Sponsor: Novartis Information: (862) 778-8300 ► Study: The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease Sponsor: National Eye Institute Information: prpl@mail.cc.nih.gov ► Study: Epigenetics, Molecular Genetics, and Biomarkers of Degenerative and Inflammatory Retinal Diseases Sponsor: National Eye Institute Information: prpl@mail.cc.nih.gov ► Study: LIME: Lucentis for Inflammatory Macular Edema Trial Sponsor: University of California, San Francisco/Genentech Information: kevin.hong@ucsf.edu ► Study: Safety, Tolerability, and Efficacy of AIN457 in the Treatment of Uveitis Sponsor: Novartis Information: (862) 778-8300 ► Study: Corticosteroid Implant vs. Oral Corticosteroid Treatment for Uveitis Sponsor: National Eye Institute Information: prpl@mail.cc.nih.gov

UVEITIS

► Study: Pegaptanib Therapy in Uveitis
Sponsor: Wake Forest University
Purpose: To evaluate the utility of pegaptanib in CME associated with noninfectious intermediate and panuveitis
Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Number of Patients: 5
Inclusion Criteria: Demonstrable (FA and/or OCT) bilateral or unilateral CME associated with uveitis of greater than 3 months but less than 1 years duration that is documented by 2 independent qualified observers; BCVA between 20/40 and 20/200 as measured by the ETDRS chart attributable to CME in the study eye; patients may be receiving systemic therapy for the treatment of their intraocular inflammation or CME, or may have been treated for the CME in the past; anterior chamber inflammation equal to or less than 1+ and vitreous inflammation equal to or less than 1+ cell and 1+ haze as per the ‘Standardization of Uveitis’ working group definition
Exclusion Criteria: Allergy to pegaptanib or any of its components; diabetic retinopathy, macular degeneration, or any other ocular condition affecting the study eye that may cause vision loss or in the opinion of the study investigator would interfere with the evaluation of the efficacy of Macugen for the treatment of uveitis associated CME; suspicion/proved history or current diagnosis, (clinical or otherwise) of infectious uveitis; need for intraocular surgery within 30 weeks of study duration; periocular steroids to the study eye less than 6 weeks prior to study enrollment; history of any prior intravitreal injections in study eye; systemic immunomodulatory agent(s) added or increased in dosage (>20%) within the last 2 months prior to study enrollment, or potential need for any increase during the study; requirement for systemic corticosteroids in the equivalent of oral prednisone >30mg/day
Information: lcooke@wfubmc.edu

► Study: Uveitis Gene-expression Profiling
Sponsor: Oregon Health and Science University
Purpose:To quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40000 gene sequences using microarray gene chip technology
Design: Case Control, Prospective
Number of Patients: 392
Exclusion Criteria: Special/vunerable subject populations (eg, mentally impaired persons and children) will not be enrolled
Information: rosenbaj@ohsu.edu

► Study: Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
Sponsor: Duke University/Childhood Arthritis and Rheumatology Research Alliance
Purpose: To examine the efficacy of infliximab for the treatment of persistent uveitis in children
Design: Active Control, Efficacy Study, Open Label, Parallel Assignment, Randomized, Treatment
Number of Patients: 40
Inclusion Criteria: Ages 4 to 18 years old; noninfectious uveitis; persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications; failure of at least 6 weeks of treatment with a nonbiological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine; ability to provide informed consent (subject or parent/guardian); onset of uveitis <16 years of age; topical ophthalmologic treatments allowed; systemic corticosteroid use at entry may be allowed; willingness to use acceptable contraception if sexually active for the duration of the study and for 6 months after receiving the last infliximab infusion; concomitant methotrexate must be taken at time of initiation of infliximab; participant must be able to cooperate for a nonsedated slit lamp exam and visual acuity examination; negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab
Exclusion Criteria: Previous use of biologic medications for uveitis; intraocular steroid injection or ophthalmologic surgery within the preceding 3 months; uveitis due to trauma or intraocular surgery; females who are pregnant, nursing, or planning pregnancy within 6 months after the last infliximab infusion; males who plan on fathering a child within 6 months after their last infliximab infusion; history of a known allergy to murine products; documentation of seropositivity for human immunodeficiency virus (HIV); documentation of a positive test for hepatitis B surface antigen or hepatitis C; known history of a serious infection (eg, hepatitis, pneumonia, or pyelonephritis) in the previous 3 months; opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening
Information: (919) 684-6575

► Study: Adalimumab (Humira) in the Treatment of Refractory Non-Infectious Uveitis
Sponsor: Oregon Health and Science University
Purpose: To assess the safety and efficacy of adalimumab in uveitis
Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study
Number of Patients: Unavailable
Inclusion Criteria: Patients with vision-threatening autoimmune uveitis; failure to respond to prednisone and at least 1 other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects
Exclusion Criteria: Serious concomitant illness that could interfere with the subject's participation in the trial; previous or current use of cyclophosphamide; unable or unwilling to undergo multiple injections
Information: suhlere@ohsu.edu

► Study: Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Sponsor: University of Miami/Genentech
Purpose: To determine if an anti-VEGF agent, Lucentis, is safe and effective in leading to regression of macular edema due to chronic noninfectious uveitis in patients with well-controlled uveitis
Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Number of Patients: 10
Inclusion Criteria: Ability to provide written informed consent and comply with study assessments for the full duration of the study; age >18 years; noninfectious uveitis in study eye; stable anti-uveitis medical regimen for at least 1 month prior to injection and controlled uveitis in the judgment of the investigator; vision 20/40 or worse in study eye; CME on fluorescein angiography (FA); OCT demonstrating thickness greater than 300 μm in the central subfield; media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria: Previous intravitreal triamcinolone injection in study eye within 3 months of study injection; use of more than 2 glaucoma medicines for study eye; significant epiretinal membrane as judged by treating physician; evidence of vitreomacular traction on OCT; previous vitrectomy in study eye; pregnancy (positive pregnancy test) or lactation; premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch; any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated; participation in another simultaneous IND trial; treatment for CME with intravitreal Lucentis, Macugen, or Avastin within 6 weeks prior to enrollment in this study
Information: talbini@med.miami.edu

► Study: Immune Responses to Antigens in Noninfectious Eye Inflammatory Diseases
Sponsor: National Eye Institute
Information: (800) 411-1222

► Study: Quality of Life and Visual Function in Uveitis Patients
Sponsor: New York Eye and Ear Infirmar
Information: (212) 979-4251

► Study: Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
Sponsor: Novartis
Information: (862) 778-8300

► Study: The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
Sponsor: National Eye Institute
Information: prpl@mail.cc.nih.gov

► Study: Epigenetics, Molecular Genetics, and Biomarkers of Degenerative and Inflammatory Retinal Diseases
Sponsor: National Eye Institute
Information: prpl@mail.cc.nih.gov

► Study: LIME: Lucentis for Inflammatory Macular Edema Trial
Sponsor: University of California, San Francisco/Genentech
Information: kevin.hong@ucsf.edu

► Study: Safety, Tolerability, and Efficacy of AIN457 in the Treatment of Uveitis
Sponsor: Novartis
Information: (862) 778-8300

► Study: Corticosteroid Implant vs. Oral Corticosteroid Treatment for Uveitis
Sponsor: National Eye Institute
Information: prpl@mail.cc.nih.gov

OTHER
► Study: Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration Sponsor: Ophthalmic Consultants of Boston/Genentech Information: jbankert@eyeboston.com

COMPLETED ENROLLMENT
► Study: Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-Related Macular Degeneration Sponsor: University of California, Davis/Genentech Information: (916) 734-6303 ► Study: Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF Sponsor: CoMentis Information: jmonk@comentis.com ► Study: Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Sponsor: MacuSight, Inc. Information: ebaj@retinalconsultantsaz.com ► Study: Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD Sponsor: Allergan Information: clinicaltrials@allergan.com ► Study: Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-VEGF in Subjects With Wet Age-Related Macular Degeneration Sponsor: Allergan Information: clinicaltrials@allergan.com ► Study: Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With DME Sponsor: MacuSight, Inc. Information: cdelpouys@macusight.com ► Study: A Multi-Center Trial to Evaluate the Safety and Efficacy of Pegaptanib Sodium (Macugen) Injected Into the Eye Every 6 Weeks for up to 2 Years for Macular Swelling Associated With Diabetes Sponsor: Pfizer Information: (800) 718-1021

COMPLETED ENROLLMENT

► Study: Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-Related Macular Degeneration
Sponsor: University of California, Davis/Genentech
Information: (916) 734-6303

► Study: Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
Sponsor: CoMentis
Information: jmonk@comentis.com

► Study: Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
Sponsor: MacuSight, Inc.
Information: ebaj@retinalconsultantsaz.com

► Study: Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD
Sponsor: Allergan
Information: clinicaltrials@allergan.com

► Study: Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-VEGF in Subjects With Wet Age-Related Macular Degeneration
Sponsor: Allergan
Information: clinicaltrials@allergan.com

► Study: Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With DME
Sponsor: MacuSight, Inc.
Information: cdelpouys@macusight.com

► Study: A Multi-Center Trial to Evaluate the Safety and Efficacy of Pegaptanib Sodium (Macugen) Injected Into the Eye Every 6 Weeks for up to 2 Years for Macular Swelling Associated With Diabetes
Sponsor: Pfizer
Information: (800) 718-1021

PentaVision

Retinal Physician

Clinical Trials Update

CLINICAL TRIAL UPDATE

Recommendations

What to Read Next

PentaVision

Retinal Physician

Clinical Trials Update

CLINICAL TRIAL UPDATE

Recommendations

What to Read Next

Chemotherapy for Retinoblastoma

Clinical Trial Spotlight

Coding Q&A

Events Calendar